Dr. Kazuhiko Nakagawa discusses the RELAY trial in epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) patients. Dr. Nakagawa talks about the effective role of ramucirumab plus erlotinib in previously untreated patients with EGFR mutation-positive metastatic NSCLC. RELAY trial increased the progression-free survival in patients with exon 21-point mutation and exon 19 deletions.1,2 Reference 1. Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y.
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research. 2019 Jun;8(3):302. 2. Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised,…